Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

Jingyu Wang; Fang Shen; Ying Yao; Lin-Lin Wang; Yongjian Zhu; Jue Hu

doi:10.3389/fonc.2020.00059

Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

Front Oncol. 2020 Jan 31:10:59. doi: 10.3389/fonc.2020.00059. eCollection 2020.

Authors

Jingyu Wang¹, Fang Shen², Ying Yao¹, Lin-Lin Wang³, Yongjian Zhu¹, Jue Hu⁴

Affiliations

¹ Department of Neurosurgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Orthopaedic Surgery's Spine Division, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
³ Department of Basic Medicine Sciences, School of Medicine, Zhejiang University, Hangzhou, China.
⁴ School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China.

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with very poor prognosis and few advances in its treatment. Recently, fast-growing cancer immunotherapy provides a glimmer of hope for GBM treatment. Adoptive cell therapy (ACT) aims at infusing immune cells with direct anti-tumor activity, including tumor-infiltrating lymphocyte (TIL) transfer and genetically engineered T cells transfer. For example, complete regressions in patients with melanoma and refractory lymphoma have been shown by using naturally tumor-reactive T cells and genetically engineered T cells expressing the chimeric anti-CD19 receptor, respectively. Recently, the administration of ACT showed therapeutic potentials for GBM treatment as well. In this review, we summarize the success of ACT in the treatment of cancer and provide approaches to overcome some challenges of ACT to allow its adoption for GBM treatment.

Keywords: Glioblastoma multiforme; T cell receptor; adoptive cell therapy; chimeric antigen receptor; tumor-infiltrating lymphocyte.

Publication types

Review